Description
ADCC-Enhanced anti-TM4SF20 (B15) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TM4SF20 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TM4SF20
Full Name
transmembrane 4 L six family member 20
Alternative Names
TM4SF20; transmembrane 4 L six family member 20; SLI5; PRO994; TCCE518; transmembrane 4 L6 family member 20
Gene ID
79853
Cellular Localization
Endoplasmic reticulum
Involvement in Disease
Diseases associated with TM4SF20 include Specific Language Impairment 5 and Specific Language Impairment.
Function
Inhibits the intramembrane proteolysis (RIP) of CREB3L1, inhibits the activation of CREB3L1 and induces the synthesis of multiple transmembrane proteins (. Ceramide changes the topology of the TM4SF20 membrane and stimulates the RIP activation of CREB3L1. Ceramide reverses TM4SF20 translation process The transmembrane spiral translocates to the direction of the endoplasmic reticulum membrane. This mechanism is called "regulated alternative translocation" (RAT), which regulates the function of transmembrane proteins.
Post-translational modifications
1.Glycosylated at Asn-132, Asn-148 and Asn-163 in presence of ceramide which inverts the orientation of TM4SF20 in membranes exposing these residues to the endoplasmic reticulum lumen 2.Modification sites at PhosphoSitePlus 3.Cleaved by signal peptidase at Ser-14 but the peptide does not act as a signal peptide. Cleavage is inhibited by ceramide which inverts the orientation of TM4SF20 in membranes exposing the N-terminus to the cytosol and not to the endoplasmic reticulum lumen 4.Modification sites at neXtProt
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
B15
Description
The antibody binding to a TM4SF20 protein can be used for the diagnosis and treatment of cancer.
Antibody Indication
Cancer
